Skip to content
BMarker
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
Menu
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
  • NCLH vs MRNA✓SelectedUSD · MRNANCLH vs MRNA performance historyLatest closeAs of-6.33%11/20
Stock and ETF performance explorer

NCLH vs MRNA

vs
1w1mo3mo6mo1y3y5y10yallcustom
Portfolio return
-30.5%
MRNA return
-27.3%
Excess return
-3.2%
Maximum drawdown
-56.2%

Performance

Returns, benchmark comparison, and relative performance.

Performance by timeframe

Returns for 5y.

Portfolio and benchmark returns by period
PeriodPortfolioMRNAExcessAlpha
1D-6.3%-2.2%-4.2%-6.1%
7D-11.0%-12.7%+1.7%-9.9%
30D+2.6%-20.7%+23.2%+4.4%
3M-4.5%+46.3%-50.8%-8.1%
6M-0.2%+305.2%-305.5%-23.0%
YTD-28.4%+561.2%-589.6%-51.7%
1Y-8.6%+772.1%-780.7%-42.4%
3Y+9.4%+147.0%-137.6%-15.7%
All-30.5%-27.3%-3.2%-47.4%

Cumulative growth

Daily Returns

Daily percentage return beside MRNA.

Daily Out/Under-Performance

Portfolio return minus MRNA return. Positive bars indicate outperformance.

Daily Alpha

Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.

Cumulative Out/Under-Performance

Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.

Cumulative Alpha

Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.

Updating return analytics…

5y analysis · Full analysis span regression · 6 months rolling